The recombinant seasonal influenza HA vaccine ASP7374 contains three different strains of antigens and has been produced by a cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS). The vaccine was developed in collaboration with UMN Pharma.

Astellas Pharma news release, May 30, 2014